Orgabio Holdings Bhd (0252) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Orgabio Holdings Bhd MYR 0.33, price MYR 0.30, upside +10.0%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Orgabio Holdings Bhd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
51‑month range 0.2300 MYR – 0.4950 MYR · fair‑value band 0.2500 MYR – 0.4200 MYR · the 0.3000 MYR price screens below the 0.3300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Orgabio Holdings Bhd in your weekly email
Every Wednesday you see whether Orgabio Holdings Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Orgabio Holdings Berhad, an investment holding company, provides instant beverage premix manufacturing services to third party brand owners. The company offers coffee, food supplement, tea, and chocolate premixes under the EveryDay and BrogaHill brand names, as well as sells aloe vera gel.
Show more
Orgabio Holdings Berhad, an investment holding company, provides instant beverage premix manufacturing services to third party brand owners. The company offers coffee, food supplement, tea, and chocolate premixes under the EveryDay and BrogaHill brand names, as well as sells aloe vera gel. It operates in Malaysia, Republic of Singapore, Hong Kong, Philippines, Taiwan, Thailand, China, Papua New Guinea, Trinidad and Tobago, and internationally. Orgabio Holdings Berhad was founded in 2002 and is headquartered in Beranang, Malaysia. Orgabio Holdings Berhad is a subsidiary of Ean Yong & Sons Sdn Bhd.
Stock analysis
Orgabio Holdings Bhd (0252) currently trades at 0.3000 MYR, while our model-based Fair Value estimate is 0.3300 MYR, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 0.5000 MYR per share, and 8 of the 14 models we run sit above the 0.3000 MYR price.
Bear case: the Asset-Based group reads lowest at 0.1600 MYR, and 6 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.2500 MYR (bear) to 0.4200 MYR (bull), the price of 0.3000 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Orgabio Holdings Bhd reported revenue of 111M MYR in FY2025 versus 59.1M MYR in FY2021, a compound +17.1%/yr. Reported net income was 3.9M MYR in FY2025, compounding −15.3%/yr from FY2021.
Key figures
Market cap 74.4M MYR (≈ $18.2M) · P/E ratio 7.5 · P/S ratio 0.27 · EPS (TTM) 0.0400 MYR · Net margin 3.5% · Return on equity 14.5% · Return on assets (EBIT) 12.3% · Operating margin 11.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 13% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at 10%, 0252 screens cheaper than that median.
Fair Value models
Bear 0.2500 MYRFair Value 0.3300 MYRBull 0.4200 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0400 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+49.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.1%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 6%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Beverages - Non-Alcoholic · 91 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+12% · Above median
Profitability
Return on equity (TTM)14% · Above median
Return on assets8% · Above median
Net margin (TTM)6% · Below median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth24% · Top 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Beverages - Non-Alcoholic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Orgabio Holdings Bhd Fair Value". https://www.fairvalue-calculator.com/stock/0252
Frequently asked questions
Is Orgabio Holdings Bhd (0252) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.3300 MYR versus a price of 0.3000 MYR, about +10% upside (undervalued).
What is the fair value of 0252?
Our model-based fair value for Orgabio Holdings Bhd is 0.3300 MYR (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.3000 MYR.
What is the quality score of 0252?
Orgabio Holdings Bhd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Orgabio Holdings Bhd (0252)?
Our model-based price target is the fair value of 0.3300 MYR (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 0.2500 MYR, optimistic scenario 0.4200 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Orgabio Holdings Bhd stock forecast for 2026?
Our models put fair value at 0.3300 MYR, about +10% upside versus a price of 0.3000 MYR (undervalued). Cautious scenario 0.2500 MYR, optimistic scenario 0.4200 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Orgabio Holdings Bhd (0252)?
Orgabio Holdings Bhd reported trailing-twelve-month revenue of about 149M MYR (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Orgabio Holdings Bhd (0252)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Orgabio Holdings Bhd it is 0.3300 MYR per share (as of Sep 24, 2026), against a price of 0.3000 MYR. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Orgabio Holdings Bhd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0252 trades below its calculated fair value: price 0.3000 MYR, fair value 0.3300 MYR, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0252?
No. The price is what the market pays today (0.3000 MYR); the fair value is what the company's own numbers justify (0.3300 MYR). For Orgabio Holdings Bhd the two are 0.0300 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Orgabio Holdings Bhd worth?
The market values Orgabio Holdings Bhd at about 74.4M MYR (market capitalisation, as of Sep 24, 2026). Per share that is 0.3000 MYR; our models calculate a fair value of 0.3300 MYR per share.
What do the bullish and bearish scenarios say about 0252?
Our models span a range for Orgabio Holdings Bhd: cautious scenario 0.2500 MYR, base 0.3300 MYR, optimistic 0.4200 MYR per share (as of Sep 24, 2026, price 0.3000 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0252?
Orgabio Holdings Bhd trades at a price-to-earnings ratio of 7.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.3300 MYR is built from several models across several years. Other multiples: P/B 0.3, P/S 0.1, EV/EBITDA 1.0.
How solid is the balance sheet of Orgabio Holdings Bhd (0252)?
Balance-sheet figures for Orgabio Holdings Bhd (as of Sep 24, 2026): return on equity 14.5%, debt of 0.12 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 0252 from its 52-week high?
Orgabio Holdings Bhd trades at 0.3000 MYR, about 8% below its 52-week high of 0.3250 MYR and 13% above the low of 0.2650 MYR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.3300 MYR is for.
Which stocks are comparable to Orgabio Holdings Bhd?
From the same area (Consumer Defensive) we also value The Coca-Cola Company, PepsiCo, Inc, Monster Beverage Corporation, Nongfu Spring Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Orgabio Holdings Bhd stock attractive at the current price?
The data as of Sep 24, 2026: price 0.3000 MYR, calculated fair value 0.3300 MYR (+10%), Quality Score 53/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0252 calculated?
We run Orgabio Holdings Bhd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.3300 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Orgabio Holdings Bhd currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Orgabio Holdings Bhd (0252)?
The closing price on Sep 24, 2026 was 0.3000 MYR. Our model-based fair value is 0.3300 MYR, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Orgabio Holdings Bhd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Orgabio Holdings Bhd
How large is the market capitalisation of Orgabio Holdings Bhd (0252)?
The market capitalisation of Orgabio Holdings Bhd is 74.4M MYR (≈ $18.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Orgabio Holdings Bhd (0252)?
The price-to-sales ratio of Orgabio Holdings Bhd is 0.27 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Orgabio Holdings Bhd (0252)?
Earnings per share at Orgabio Holdings Bhd are 0.0400 MYR (price ÷ EPS = P/E 7.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Orgabio Holdings Bhd (0252)?
The net margin of Orgabio Holdings Bhd is 3.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Orgabio Holdings Bhd (0252)?
The return on equity (ROE) of Orgabio Holdings Bhd is 14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Orgabio Holdings Bhd (0252)?
On an EBIT basis the return on assets of Orgabio Holdings Bhd is 12.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Orgabio Holdings Bhd (0252)?
The operating margin of Orgabio Holdings Bhd is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Orgabio Holdings Bhd (0252)?
Revenue at Orgabio Holdings Bhd is growing +24.3% versus a year earlier (3y avg +19.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Orgabio Holdings Bhd (0252)?
Earnings per share at Orgabio Holdings Bhd are growing +193% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Orgabio Holdings Bhd (0252) generate?
The free cash flow of Orgabio Holdings Bhd is −4.3M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Orgabio Holdings Bhd (0252) carry?
The net debt of Orgabio Holdings Bhd is 1.1M MYR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Orgabio Holdings Bhd in the live analysis
One click puts Orgabio Holdings Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
